Rapid Microbiology Testing Market Size, Share and Forecast to 2026

 The report "Rapid Microbiology Testing Market by Product (Reagents, Kits, Automated Identification System, PCR, Mass Spectrometry), Method (Growth, Nucleic Acid, Viability), Applications (Clinical Diagnosis, Pharma, Environmental) - Global Forecast to 2026", The global rapid microbiology testing market is projected to reach USD 6.7 billion by 2026 from USD 4.2 billion in 2021, at a CAGR of 9.4%.



Key Players:

Abbott Laboratories, Inc. (US), Becton, Dickinson and Company (US), bioMérieux SA (France), Bruker Corporation (US), Charles River Laboratories International, Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), NEOGEN Corporation (US), Quidel Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific, Inc. (US), Don Whitley Scientific Limited (UK), Rapid Micro Biosystems, Inc. (US), Vivione Biosciences, LLC (US), Gradientech (Sweden), rqmicro AG (Switzerland), Bactest Ltd. (US), Colifast (Norway), Serosep Ltd. (Ireland), Biosensia (Ireland), Solus Scientific Solutions Ltd. (Scotland), LubioScience GmbH (Scotland), Euroclone SpA (Italy), CorDx (US), and R-Biopharm AG (Germany).

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=31548521

Increasing incidence of infectious disease and cancer, technological advancements in rapid microbiology testing, increased funding for R&D and increased focus on the early detection of infectious disease are among the other factors. Emerging economies such as China, India, and Japan are providing lucrative opportunities for the players operating in the rapid microbiology testing market.

The cardiac Instruments segment accounted for the largest share of the rapid microbiology testing market, by product segment, in 2020

Based on product, the rapid microbiology testing market is segmented into instruments, reagents and kits, and consumables. The instruments segment accounted for the largest share of the rapid microbiology testing market in 2020. Factors such as technological advancements, increasing incidence of infectious disease and cancer and increased focus on the early detection of infectious disease are contributing to the growth of this market.

Nucleic acid-based rapid microbiology testing segment to register the highest growth rate during the forecast period

The rapid microbiology testing market is segmented into growth-based, nucleic acid-based, viability-based, cellular component-based, and another rapid microbiology testing. In 2020, the nucleic acid-based segment accounted for the highest growth rate. Factors such as the increased focus on early detection of infectious disease and rising incidence of infectious diseases and cancer.

Request Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=31548521

The clinical disease diagnostics segment accounted for the largest share of the rapid microbiology testing market, by applications segment, in 2020

Based on applications, the rapid microbiology testing market has been segmented into clinical disease diagnosis, food and beverage testing, pharmaceutican and biological drug testing, environmental testing, cosmetics, and personal care products testing, research applications, and other applications. In 2020, the clinical disease diagnostics segment accounted for the largest share of the rapid microbiology testing market. The increasing incidence of infectious disease and cancer is driving this segments growth.

North America is the largest regional market for rapid microbiology testing market

The global rapid microbiology testing market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the rapid microbiology testing market. The large share of this region can be attributed to the increased funding on R&D and technological advancements in the US and Canada.

Buy Now:

https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=31548521

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: 1-888-600-6441

Email: sales@marketsandmarkets.com

Comments

Post a Comment

Popular posts from this blog

Healthcare Simulation Market Size & Share - Global Future Growth Predictions

Image
 The global healthcare simulation market is projected to reach USD 4.6 billion by 2028 from USD 2.2 billion in 2023, at a high CAGR of 15.7% during the forecast period. The expansion of this market is fueled by the increasing adoption of advanced techniques and methodologies in delivering medical education, along with restricted patient access during medical training. Nevertheless, the market's growth is anticipated to be somewhat hampered by the constrained availability of funds and incomplete replication of medical simulators. Market Size Introduction: The healthcare simulation market size represents the total valuation of products and services within the healthcare simulation industry over a specific period, typically a year. It encompasses various simulation technologies, including manikins, simulators, simulated environments, and software solutions, utilized for medical training, education, and research purposes. Understanding the market size is crucial for stakeholders as ...
Read more

Global Dental Practice Management Software Industry worth $2.3 billion By 2028

Image
 The Global Dental Practice Management Software Market in terms of revenue was estimated to be worth $1.5 billion in 2023 and is poised to reach $2.3 billion in 2028, growing at a CAGR of 8.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The rising awareness of oral hygiene and dental treatment, the increasing demand for advanced dental procedures, and the growing market for dental tourism in developing countries are major key drivers for the market. However, data privacy and security issues are the factors which may slow down market growth. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153532396 Dental Practice Management Software Industry Dynamics Driver: Rising demand for advanced cosmetic dental procedures Cosmetic d...
Read more

Humanized Mouse and Rat Model Market worth $349 million by 2028

Image
  In the near future, the humanized mouse and rat model industry is set to undergo transformative advancements, revolutionizing biomedical research and drug development. These cutting-edge models, where mice and rats are genetically modified to possess human-like characteristics and immune systems, will play a pivotal role in bridging the gap between preclinical studies and clinical trials. Through refined genetic engineering techniques, these models will closely mimic human physiology, enabling more accurate and predictive assessments of drug safety, efficacy, and disease mechanisms. Moreover, the industry will witness the integration of advanced technologies, such as CRISPR/Cas9, to expedite the creation of customized humanized models, tailoring them to specific diseases or individual patient profiles. These advancements will spur collaboration between academia, pharmaceutical companies, and biotech firms, fostering a dynamic research ecosystem focused on targeted therapies and p...
Read more